Domino's Pizza, Inc. vs Pfizer Inc — how do they compare? Domino's Pizza, Inc. trades at $310.09 (market cap $10.31B), while Pfizer Inc trades at $24.72 (market cap $138.21B). The key difference: Pfizer Inc is far larger — about 13.4× Domino's Pizza, Inc.'s market cap, and Pfizer Inc pays the higher dividend (7.09%). Which is the better fit depends on your goals.
| DPZ | PFE | |
|---|---|---|
Market Cap | $10.31B | $138.21B |
Sector | Consumer Cyclical | Health |
52-Week High | $485.53 | $28.56 |
52-Week Low | $282.89 | $23.29 |
Enterprise Value | $15.21B | $188.87B |
Dividend Yield | 2.57% | 7.09% |
Volume | — | 29,869,932 |
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $309.85, up 3.47% today, with a neutral technical signal and bearish moving averages. The company reported Q1 2026 EPS of $4.13, missing expectations, but maintains strong profitability with a net margin of 11.89%. Recent news includes CEO succession and new product launches, while analyst consensus remains bullish with a $380.31 price target.
DPZ offers steady growth and a 2.66% dividend yield, but faces risks from slowing same-store sales and high debt. The stock's valuation at 17.84x P/E is reasonable, yet competitive pressures and macroeconomic headwinds warrant caution. Upside potential exists if Q2 earnings beat expectations and new leadership reinvigorates growth.
Pfizer (PFE) trades at $24.48, up 1.28% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $0.75 surpassing the $0.722 estimate. The company maintains solid profitability with a 73.51% gross margin and 11.83% net margin, while cash flow trends show positive net cash generation in 2025. News highlights focus on Pfizer's pipeline developments in obesity and oncology therapies.
The stock presents a value opportunity with a P/E of 18.51 below industry averages and a consensus price target of $28.78 implying 18% upside. However, risks include patent expirations, competitive pressures, and debt levels near 31% of assets. Analyst sentiment is mixed with 38% buy ratings versus 59% hold, suggesting cautious optimism amid pipeline execution uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →